TY - JOUR
AU - Denk, Dominic
AU - Ramakrishnan, Mallika
AU - Conche, Claire
AU - Pallangyo, Charles
AU - Pesic, Marina
AU - Ceteci, Fatih
AU - Kennel, Kilian B
AU - Kirisözü, Asude C
AU - Engel, Esther
AU - Mohs, Kathleen
AU - Ritter, Birgit
AU - Pardo, Angeles Macias
AU - Özkurt, Ezgi
AU - Hildebrand, Falk
AU - Waisman, Ari
AU - Arkan, Melek C
AU - Greten, Florian R
TI - IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis.
JO - Immunity
VL - 58
IS - 3
SN - 1074-7613
CY - [Cambridge, Mass.]
PB - Cell Press
M1 - DKFZ-2025-00469
SP - 701-715.e8
PY - 2025
N1 - 2025 Mar 11;58(3):701-715.e8
AB - Expression of interleukin (IL)-17 family cytokines is associated with tumor-promoting inflammation. We found that low expression of IL17RA associated with worse prognosis in late-stage colorectal cancer (CRC) patients. Deletion of Il17ra in intestinal epithelial cells (IECs) in a murine model of CRC enhanced epithelial-to-mesenchymal transition (EMT) via increased expression of the epidermal growth factor receptor and subsequent activation of the kinase Src. Yet, these mice were protected from metastatic disease; Il17ra deletion impaired intestinal barrier function and enhanced systemic fungal invasion and associated immunity. However, in macrophages, IL-17RA was required for spleen tyrosine kinase (Syk) activation upon fungal-induced dectin-1 engagement, and Il17ra ablation impaired IL-18 release and protective CD8+ T cell-mediated anti-tumor immunity. Combining recombinant IL-17 and heat-killed Candida albicans rendered colorectal tumors sensitive to α-PD-1 treatment in a model of microsatellite stable (MSS) CRC. Thus, IL-17RA engages two distinct tumor-suppressive mechanisms in CRC, linking EMT and fungal-induced anti-tumor immunity during tumor progression.
KW - CRC (Other)
KW - EMT (Other)
KW - IL-17 (Other)
KW - IL-17RA (Other)
KW - anti-tumor immunity (Other)
KW - colon cancer (Other)
KW - immunotherapy (Other)
KW - inflammation (Other)
KW - mycobiome (Other)
LB - PUB:(DE-HGF)16
C6 - pmid:40023157
DO - DOI:10.1016/j.immuni.2025.02.005
UR - https://inrepo02.dkfz.de/record/299511
ER -